Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin E Combined With Radiation Increases Risk Of Second Cancer – Study

This article was originally published in The Tan Sheet

Executive Summary

Vitamin E supplementation significantly increased the risk of second primary cancer in patients undergoing radiation treatment for head or neck cancer, according to a study recently published in the Journal of the National Cancer Institute

You may also be interested in...



Beta carotene/vitamin A cancer trial stopped early due to efficacy, safety concerns.

NCI-FUNDED BETA CAROTENE/VITAMIN A TRIAL ON LUNG CANCER HALTED PREMATURELY in response to interim data indicating a lack of efficacy and possible adverse events, the National Cancer Institute announced Jan. 18. The active intervention phase of the six-center Beta Carotene and Retinol Efficacy Trial (CARET) in 18,000 high-risk men and women was slated originally to close in September 1997.

BETA CAROTENE FAILS TO REDUCE LUNG CANCER RISK IN HEAVY SMOKERS

BETA CAROTENE FAILS TO REDUCE LUNG CANCER RISK IN HEAVY SMOKERS enrolled in a Finnish study of 29,133 male long-term smokers aged 50 to 69 years that appears in the April 14 New England Journal of Medicine. In fact, subjects receiving 20 mg beta carotene daily showed an 18% increase in lung cancer incidence. The clinical trial results on beta carotene and vitamin E supplements for the prevention of lung cancer are the first published analyses of the data from the long-term Alpha- Tocopherol, Beta Carotene (ATBC) Cancer Prevention Study.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel